Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 5 | 119 | 37% |
| 2020 | 3 | 92 | 40% |
| 2021 | 2 | 93 | 43% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Washington; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 14 | 436+11%/yr | +11%/yr | 0.1 | 28% | 770 in 2030+9.8%/yr |
| Arizona | 8 | 188 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 24 | 2,704+1.8%/yr | +1.8%/yr | 3.60.7× | 77% | 3,880 in 2030+6.2%/yr |
| Ear tubes & middle ear surgery |
Cochlear implants in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
| 2024 |
| 144 |
| 54% |
| 2025 est. | ≈ 210 | – |
| 2026 est. | ≈ 230 | – |
| 2022 | 6 | 126 | 46% |
| 2023 | 5 | 115 | 50% |
| 2024 | 3 | 144 | 54% |
| 2025 from claims | – | 208 168–245 | 54% |
| 2026 forecast | – | 229 179–287 | 54% |
| 2027 forecast | – | 248 184–328 | 55% |
| 2028 forecast | – | 269 190–371 | 56% |
| 2029 forecast | – | 291 198–418 | 57% |
| 2030 forecast | – | 316 207–468 | 57% |
In 2025, 67% hospital outpatient, 33% surgery center.
| +10%/yr |
| 0.3 |
| 0% |
| 200 in 2030+1%/yr |
| Colorado | 4 | 157+3.7%/yr | +3.7%/yr | 0.3 | 0% | 110 in 2030−5.3%/yr |
| 1 |
| 192−8%/yr |
| −8%/yr |
| 0.31.2× |
| 100% |
| 240 in 2030+3.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Advanced Bionics leads with 71% of company spending on these surgeons in 2025, +69 pts on 2024.
In 2025, 7 companies reported engagement with Washington’s surgeons worth $78K in consulting, speaking, meals and travel tied to these products, about $26K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.